There is no federal law in the United States requiring blood work before a clinician prescribes a GLP-1 medication. That's not an oversight — it's a regulatory reality that creates a wide spectrum of clinical rigor across telehealth platforms. Some platforms order comprehensive metabolic panels before writing a single prescription. Others hand you a semaglutide script after a five-minute asynchronous questionnaire with zero lab work.
Both approaches are technically legal. Only one meets the standard of care that major medical organizations recommend.
What the Medical Guidelines Actually Say
While no law mandates labs, the clinical consensus is clear. The American Diabetes Association (ADA) Standards of Medical Care recommend HbA1c, renal function, and lipid panels as part of baseline metabolic assessment before initiating GLP-1 therapy in patients with diabetes. The American Association of Clinical Endocrinology (AACE) guidelines for obesity management similarly recommend comprehensive metabolic evaluation prior to weight loss pharmacotherapy, including thyroid assessment when clinically indicated.
The Obesity Medicine Association (OMA) position statement on telehealth prescribing emphasizes that asynchronous or remote prescribing should not lower the clinical standard of care. Translated: just because you're prescribing through a screen doesn't mean you get to skip the workup.
The FDA has received hundreds of adverse event reports linked to compounded semaglutide and compounded tirzepatide. Many involved dosing errors from self-administration of multidose vials — errors that proper baseline assessment and ongoing monitoring might have caught or prevented.
What Baseline Labs Actually Catch
Pre-treatment bloodwork isn't bureaucratic busywork. It screens for conditions that can make GLP-1 therapy risky, less effective, or medically inappropriate:
- Thyroid function (TSH): GLP-1 medications carry a boxed warning about thyroid C-cell tumors. Baseline thyroid screening identifies existing thyroid issues before adding a medication that acts on thyroid pathways.
- Kidney function (eGFR, creatinine): GLP-1s are associated with potential kidney effects. Patients with existing kidney disease need dose adjustments and closer monitoring.
- Pancreatic markers (lipase, amylase): Pancreatitis is a known GLP-1 risk. Elevated baseline pancreatic enzymes are a contraindication that only bloodwork reveals.
- HbA1c and fasting glucose: Identifies undiagnosed diabetes or prediabetes, which affects medication choice and dosing protocol.
- Liver function (ALT, AST): GLP-1s show promise for fatty liver disease, but baseline liver values establish a reference point for monitoring.
- Lipid panel: Establishes cardiovascular risk profile and provides a baseline to measure treatment benefits.
How Major Telehealth Platforms Compare on Labs
The differences across platforms are significant. Based on available reporting and platform documentation as of spring 2026:
Minimal or no lab requirements: Several major platforms — including Hims (pre-settlement) and Henry Meds — historically did not require or routinely request bloodwork before prescribing. The clinical intake relied on patient-reported health history and, in some cases, asynchronous review without a live consultation.
Labs available but not required: Some platforms offer at-home lab testing as an add-on service but don't make it a prerequisite for prescribing. This puts the decision on the patient, who may not understand why labs matter.
Labs required before prescribing: Platforms like Calibrate and Mochi Health require baseline metabolic workups before initiating therapy. These platforms typically charge more but include monitoring as part of the program.
Comprehensive metabolic monitoring: A smaller tier of platforms includes ongoing lab monitoring at regular intervals — not just baseline — and uses the results to adjust treatment. This is the closest telehealth equivalent to what you'd get from an endocrinologist or obesity medicine specialist.
What to Ask Your Telehealth Provider
Before enrolling in any GLP-1 telehealth program, ask these five questions:
- Do you require baseline blood work before prescribing? If not, why not?
- Which specific labs do you order? A comprehensive panel should include at minimum thyroid, kidney, pancreatic, and metabolic markers.
- How do you handle existing conditions identified by labs? Do they refer out, adjust treatment, or just proceed?
- Do you monitor labs during treatment? At what intervals? What triggers retesting?
- What happens if my labs are abnormal? Is there a protocol, or does the clinician wing it?
If a platform can't clearly answer these questions, that tells you something about the depth of their clinical model.
The Emerging Standard
The GLP-1 telehealth market is maturing, and lab monitoring is becoming a competitive differentiator. Hims' May 2026 launch of Labs AI — covering 130 biomarker tests across 10 health categories with AI-assisted interpretation — signals that even high-volume, low-friction platforms are recognizing that monitoring matters. Whether AI interpretation matches physician-level clinical judgment remains to be seen, but the direction is clear: the industry is moving toward more monitoring, not less.
For patients, the best approach is to insist on baseline labs regardless of whether your platform requires them. If your telehealth provider won't order them, get them done through your primary care physician or a direct-to-consumer lab service, and share the results before starting treatment.